04:37 PM EDT, 10/02/2024 (MT Newswires) -- Arcus Biosciences ( RCUS ) said Wednesday it is collaborating with AstraZeneca ( AZN ) in a clinical trial to evaluate a combination of casdatifan with volrustomig to treat patients with clear cell renal cell carcinoma.

Casdatifan is Arcus's investigational and volrustomig is AstraZeneca's ( AZN ) investigational PD-1/CTLA-4 bispecific antibody. This is the second collaboration between the firms on drug trials.

AstraZeneca ( AZN ) will sponsor and operationalize the study to evaluate the safety and early efficacy of the treatment in advanced ccRCC.

In 2020, the duo announced a collaboration for a phase 3 study in patients with unresectable stage III non-small cell lung cancer.